A Look At BridgeBio Pharma (BBIO) Valuation After New ATTR-CM, LGMD2I/R9 And TTR Antibody Updates

Why BridgeBio Pharma stock is back in focus

BridgeBio Pharma (BBIO) has returned to the spotlight after management outlined fresh clinical and commercial milestones around its ATTR-CM franchise, the FORTIFY Phase 3 program in LGMD2I/R9, and a new TTR amyloid depleter antibody effort.

For investors, the combination of growing real-world use of acoramidis, FDA feedback on a potential full approval filing for BBP-418, and the planned TTR antibody program creates a fuller picture of BridgeBio’s current pipeline priorities.

See our latest analysis for BridgeBio Pharma.

The recent clinical updates and conference appearances come against a backdrop of strong share price momentum, with a 43.76% 90 day share price return and very large 3 year total shareholder return, which suggests investors are reacting strongly to BridgeBio Pharma’s pipeline progress and changing risk outlook.

If you are looking beyond BridgeBio Pharma for other ideas in the sector, this could be a good moment to scan healthcare stocks for more potential opportunities in healthcare.

With BridgeBio Pharma showing strong recent returns, a US$79.11 share price and an intrinsic value estimate implying a sizeable discount, investors may be asking whether there is still upside or whether the market is already pricing in future growth.

Most Popular Narrative: 6.5% Undervalued

With BridgeBio Pharma closing at US$79.11 against a narrative fair value of about US$84.65, the current price sits below that central estimate and sets up a valuation story driven by aggressive growth and margin assumptions.

The analysts have a consensus price target of $63.81 for BridgeBio Pharma based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $95.0, and the most bearish reporting a price target of just $41.0.

Read the complete narrative.

Want to see what kind of revenue trajectory and margin shift would support a premium future earnings multiple in a rare disease biotech? The most widely followed narrative leans on ambitious growth, a sharp swing into profitability, and a rich valuation multiple to arrive at its fair value. Curious how those moving parts fit together over the next few years?

Result: Fair Value of $84.65 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, there are still real swing factors here, including Attruby dependence and the risk that key Phase 3 programs or regulatory timelines do not play out as expected.

Find out about the key risks to this BridgeBio Pharma narrative.

Another Angle On Valuation

So far, the story has leaned on a narrative fair value of about US$84.65, which points to BridgeBio Pharma looking 6.5% undervalued at a share price of US$79.11. The SWS DCF model, however, points to a much higher fair value of US$273.73, which implies the stock trades at a steep discount to that cash flow view. When two methods point to very different outcomes, investors may wish to consider which approach better aligns with the risks and execution hurdles that lie ahead.

Look into how the SWS DCF model arrives at its fair value.

Build Your Own BridgeBio Pharma Narrative

If you see the assumptions differently or want to weigh the risks and cash flows for yourself, you can build a custom view in minutes with Do it your way.

A great starting point for your BridgeBio Pharma research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If BridgeBio Pharma has caught your attention, do not stop here. Broaden your watchlist with other focused ideas that could sharpen your next investing move.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com